Login to Your Account

'Draconian' ESA Plan Likely To Change

Kidney Limits Favor Amgen, Awaiting CMS Cancer Word

By Randall Osborne

Tuesday, July 24, 2007
Amgen Inc.'s stock gained ground as investors listened to pundits give forth their opinions on federal reimbursement changes disclosed Friday for the high-selling Aranesp (darbepoetin alfa) and Epogen (epoetin alfa), when used in kidney disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription